NONSTEROIDAL ANTI-INFLAMMATORY DRUG-SPARING EFFECT OF SECUKINUMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS: 4-YEAR RESULTS FROM THE MEASURE 2, 3 AND 4 PHASE 3 TRIALS

被引：0
|
作者：
Dougados, M. [1 ]
Kiltz, U. [2 ,3 ]
Kivitz, A. [4 ]
Pavelka, K. [5 ]
Rohrer, S. [5 ]
Mccreddin, S. [7 ]
Quebe-Fehling, E. [6 ]
Porter, B. [8 ]
Talloczy, Z. [8 ]
机构：
[1] Univ Paris, Dept Rheumatol, Hop Cochin, Paris, France
[2] Rheumazentrum Ruhrgebiet, Herne, Germany
[3] Ruhr Univ, Bochum, Germany
[4] Altoona Ctr Clin Res, Duncansville, PA USA
[5] Inst Rheumatol, Dept Rheumatol, Prague, Czech Republic
[6] Novartis Pharma AG, Basel, Switzerland
[7] Novartis Ireland Ltd, Dublin, Ireland
[8] Novartis Pharmaceut, E Hanover, NJ USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷
关键词：
D O I：
10.1136/annrheumdis-2020-eular.824
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0374
引用
收藏
页码：415 / 416
页数：2
相关论文
共 50 条
  • [21] INCIDENCE OF INFLAMMATORY BOWEL DISEASE IN PATIENTS TREATED WITH SECUKINUMAB: POOLED ANALYSIS OF 21 RANDOMISED CONTROLLED PHASE 3/ 4 CLINICAL TRIALS OF PSORIASIS, PSORIATIC ARTHRITIS, AND ANKYLOSING SPONDYLITIS
    Schreiber, Stefan
    Colombel, Jean-Frederic
    Feagan, Brian G.
    Reich, Kristian
    Deodhar, Atul
    McInnes, Iain B.
    Porter, Brian
    Das Gupta, Ayan
    Pricop, Luminita
    Fox, Todd
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 18 - 18
  • [22] SECUKINUMAB IMPROVES PHYSICAL FUNCTION AND QUALITY OF LIFE IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 2-YEAR DATA FROM MEASURE 1, A PHASE 3 RANDOMISED TRIAL
    Emery, P.
    Baeten, D.
    Deodhar, A.
    Wei, A.
    Geusens, P.
    Talloczy, Z.
    Gong, Y.
    Porter, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 818 - 818
  • [23] Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1
    Braun, Juergen
    Buehring, Bjoern
    Baraliakos, Xenofon
    Gensler, Lianne S.
    Porter, Brian
    Quebe-Fehling, Erhard
    Haemmerle, Sibylle
    BMC MUSCULOSKELETAL DISORDERS, 2021, 22 (01)
  • [24] Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1
    Jürgen Braun
    Bjoern Buehring
    Xenofon Baraliakos
    Lianne S. Gensler
    Brian Porter
    Erhard Quebe-Fehling
    Sibylle Haemmerle
    BMC Musculoskeletal Disorders, 22
  • [25] THE EFFECT OF ANTI-TUMOR NECROSIS FACTOR THERAPY WITH GOLIMUMAB ON RADIOGRAPHIC PROGRESSION IN DEFINITE ANKYLOSING SPONDYLITIS: 4-YEAR RESULTS
    Braun, J.
    van der Heijde, D.
    Hermann, K. -G.
    Baraliakos, X.
    Deodhar, A.
    Beutler, A.
    Mack, M.
    Xu, W.
    Hsu, B.
    Inman, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 249 - 249
  • [26] THE EFFECT OF ANTI-TUMOR NECROSIS FACTOR THERAPY WITH GOLIMUMAB ON RADIOGRAPHIC PROGRESSION IN DEFINITE ANKYLOSING SPONDYLITIS: 4-YEAR RESULTS
    Braun, J.
    van der Heijde, D.
    Hermann, K. G.
    Baraliakos, X.
    Deodhar, A.
    Beutler, A.
    Mack, M.
    Xu, W.
    Hsu, B.
    Inman, R.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2012, 30 (04) : 604 - 604
  • [27] Secukinumab Demonstrates Sustained Efficacy and Safety in a Taiwanese Subpopulation With Active Ankylosing Spondylitis: Four-Year Results From a Phase 3 Study, MEASURE 1
    Tseng, Jui-Cheng
    Wei, James Cheng-Chung
    Deodhar, Atul
    Martin, Ruvie
    Porter, Brian
    McCreddin, Suzanne
    Talloczy, Zsolt
    FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [28] . SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS: 2-YEAR RESULTS FROM A PHASE 3 TRIAL WITH SUBCUTANEOUS LOADING AND MAINTENANCE DOSING (MEASURE 2)
    Marzo-Ortega, Helena
    Sieper, Joachim
    Kivitz, Alan
    Blanco, Ricardo
    Cohen, Martin
    RHEUMATOLOGY, 2017, 56 : 94 - 94
  • [29] Evaluation of the Nonsteroidal Anti-Inflammatory Drug-Sparing Effect of Etanercept in Axial Spondyloarthritis: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.
    Dougados, Maxime
    Wood, Emily
    Combe, Bernard
    Miceli-Richard, Corinne
    Berenbaum, Francis
    Koppiker, Nandan
    Dubanchet, Arnaud
    Logeart, Isabelle
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S255 - S256
  • [30] EVALUATION OF THE NONSTEROIDAL ANTI-INFLAMMATORY DRUG-SPARING EFFECT OF ETANERCEPT IN AXIAL SPONDYLOARTHRITIS: RESULTS OF THE MULTICENTER RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SPARSE TRIAL
    Dougados, M.
    Wood, E.
    Combe, B.
    Miceli-Richard, C.
    Berenbaum, F.
    Koppiker, N.
    Dubanchet, A.
    Logeart, I.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 722 - 723
12345